Photo of Osama Rahma,  MD

Osama Rahma, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Osama Rahma, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School
  • Physician/Assistant Professor, Medical Oncology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

I am a Medical Oncologist who specializes in GI Oncology, with a research focus on Cancer Immunotherapy. After finishing my fellowship training at NCI, I joined UVA to lead a Clinical and Translational Research Program in Hepatobiliary Cancer. I recently joined the Center for Immuno-Oncology and GI Oncology to conduct immunotherapy clinical trials in a variety of malignancies, in addition to providing clinical care to patients with GI cancers. I also have an appointment as an Associate Physician in Medical Oncology at Brigham and Women’s Hospital.

We are currently investigating combination of immunotherapeutics including immune checkpoint inhibitors and costimulatory molecule agonists in variety of cancers. In addition we are leading the efforts of moving immunotherapy to GI cancers. We are

investigating a novel immunotherapy approach in the treatment of pancreatic and rectal cancer combining chemoradiation with anti-PD-1 before surgical resection.

Publications

Powered by Harvard Catalyst
  • Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 2016. PubMed
  • Millard T, Kunk PR, Ramsdale E, Rahma OE. Current debate in the oncologic management of rectal cancer. World J Gastrointest Oncol 2016; 8:715-724. PubMed
  • Newhook TE, Lindberg JM, Adair SJ, Kim AJ, Stelow EB, Rahma OE, Parsons JT, Bauer TW. Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis. Ann Surg Oncol 2016; 23:1993-2000. PubMed
  • Gentzler R, Hall R, Kunk PR, Gaughan E, Dillon P, Slingluff CL, Rahma OE. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. 2016; 8:583-600. PubMed
  • Kunk PR, Bauer TW, Slingluff CL, Rahma OE. From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. J Immunother Cancer 2016; 4:14. PubMed
  • Verla-Tebit E, Rahma OE. Regression of hepatocellular carcinoma after treatment of hepatitis C: a case report. J Gastrointest Oncol 2015; 6:E52-4. PubMed
  • Ulahannan SV, Rahma OE, Duffy AG, Makarova-Rusher OV, Kurtoglu M, Liewehr DJ, Steinberg SM, Greten TF. Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades. Hepat Oncol 2015; 2:39-50. PubMed
  • Carrera C, Kunk P, Rahma O. Small Cell Carcinoma of the Gallbladder: Case Report and Comprehensive Analysis of Published Cases. J Oncol 2016; 2015:304909. PubMed
  • Ulahannan SV, Duffy AG, McNeel TS, Kish JK, Dickie LA, Rahma OE, McGlynn KA, Greten TF, Altekruse SF. Earlier presentation and application of curative treatments in hepatocellular carcinoma. Hepatology 2014; 60:1637-44. PubMed
  • Rahma OE, Gammoh E, Simon RM, Khleif SN. Is the "3+3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design. Clin Cancer Res 2014; 20:4758-67. PubMed
  • Zakharia Y, Rahma O, Khleif SN. Ovarian cancer from an immune perspective. Radiat Res 2014; 182:239-51. PubMed
  • Rahma OE, Herrin VE, Ibrahim RA, Toubaji A, Bernstein S, Dakheel O, Steinberg SM, Abu Eid R, Mkrtichyan M, Berzofsky JA, Khleif SN. Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer. J Transl Med 2014; 12:353. PubMed
  • Rahma OE, Hamilton JM, Wojtowicz M, Dakheel O, Bernstein S, Liewehr DJ, Steinberg SM, Khleif SN. The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med 2014; 12:55. PubMed
  • Gaertner KM, Caldwell SH, Rahma OE. A case of retinal tear associated with use of sorafenib. 2014; 4:196. PubMed
  • Rahma OE, Burotto M, Do Canto LM, Germanos AA, Haddad BR, Marshall JL. Striking similarities in genetic aberrations between a rectal tumor and its lung recurrence. World J Gastrointest Oncol 2013; 5:198-203. PubMed
  • Duffy A, Rahma O, Greten TF. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Stu Int. J. Cancer 2013; 132:1718. PubMed
  • Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S, Herrin VE, Shams MA, Steinberg SM, Merino M, Gooding W, Visus C, Deleo AB, Wolf JK, Bell JG, Berzofsky JA, Whiteside TL, Khleif SN. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother 2012; 61:373-84. PubMed
  • Rahma OE, Greten TF, Duffy A. Locally advanced cancer of the esophagus, current treatment strategies, and future directions. 2012; 2:52. PubMed
  • Rahma OE, Khleif SN. Therapeutic vaccines for gastrointestinal cancers. Gastroenterol Hepatol (N Y) 2012; 7:517-64. PubMed
  • Rahma OE, Ashtar E, Ibrahim R, Toubaji A, Gause B, Herrin VE, Linehan WM, Steinberg SM, Grollman F, Grimes G, Bernstein SA, Berzofsky JA, Khleif SN. A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. J Transl Med 2010; 8:8. PubMed
Hide